Markus Jensen
Innate Pharma (France) · 19 works · 1,628 citations · h-index 10
Top works
- SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
- Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine
- Fludarabine in Combination With Alemtuzumab Is Effective and Feasible in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia: Results of a Phase II Trial
- Seventy-five years of Resochin® in the fight against malaria
- Targeting the neural cell adhesion molecule in cancer
- Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia
- PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients
- Specific Activation of Resting T Cells Against CA19–9+ Tumor Cells by an Anti-CD3/CA19–9 Bispecific Antibody in Combination with a Costimulatory Anti-CD28 Antibody
- Effect of Diet on Serum Creatinine in Healthy Subjects During a Phase I Study
- The Novel Chimeric Anti-NCAM (Neural Cell Adhesion Molecule) Antibody ch.MK1 Displays Antitumor Activity in SCID Mice but Does not Activate Complement-Dependent Cytolysis (CDC)
- NK cell depletion diminish tumour-specific B cell responses
- Localization of 131I-labelled monoclonal antibody ERIC1 in a subcutaneous xenograft model of neuroblastoma in SCID mice
- One Step Generation of Fully Chimeric Antibodies Using Cγ1- and Cκ Mutant Mice
- A phase 1, open-label, multi-center study of the safety, tolerability, and efficacy of IPH4502 as a single agent in advanced solid tumors.
- Abstract CT231: Dual CD39 and PD-L1 inhibition: Interim results from the phase 2 MATISSE trial of IPH5201 plus durvalumab (durva) and platinum-based chemotherapy (CT) in patients (pts) with resectable NSCLC
- Construction, expression and binding specificity of bispecific CD3 × VEGFR-2 and CD3 × NCAM antibodies in the single chain and diabody format
- Abstract 15196: A Novel Balanced Dual Vasopressin V1a/V2 Receptor Antagonist for Treatment of Congestive Heart Failure: Results From a First-in-Man Study
- Radio-labeled ERIC1: Relationship of biodistribution to the labeling nuclide and linker in neuroblastoma-bearing mice
- Prolonged Remission in a Patient with Relapsed Follicular Lymphoma after a Single Course of Rituximab